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ardiovascular medications may cause,exacer-
bate,or relieve neuropsychiatric symptoms.Historically,
a host of medications with effects on the cardiovascular
system have been associated with the development of
depression,anxiety,psychosis,or delirium,while others
have been thought to have antidepressant or antimanic
effects.However,there are several factors that make it
difficult to confirm whether a given cardiovascular med-
ication causes a given neuropsychiatric symptom.
First,neuropsychiatric symptoms are exceedingly common
among patients with cardiovascular conditions.For exam-
ple,approximately 15% of patients with recent myocardial
infarction (MI),congestive heart failure (CHF),or recent
coronary artery bypass graft (CABG) surgery suffer from
major depressive disorder (MDD).
1-3Anxiety is also com-
mon among patients with coronary artery disease (CAD),
especially among post-MI patients.
2,4,5 Finally, delirium,
which can present with psychotic symptoms,mood lability,
and anxiety,is highly prevalent among hospitalized cardiac
patients,especially among those undergoing surgery.
6Thus,
it may appear that a particular cardiovascular medication
frequently causes a particular neuropsychiatric syndrome,
when in fact such a syndrome may occur commonly as part
of the natural history of cardiac illness,and be unrelated to
medication.In addition,the vast majority of studies that
associate cardiovascular medications with neuropsychiatric
consequences have been case reports and case series that
may at best suggest a link between the taking of a medica-
tion and a clinical outcome.Such reports do not usually use
standardized tools to evaluate the presence or severity of
the reported neuropsychiatric symptoms;instead,they rely
only on  general reports of symptoms as observed by the
authors.As we will discuss,well-controlled trials that exam-
ine the neuropsychiatric consequences of cardiovascular
medications are relatively few and far between, and at
times may contradict clinical reports.
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The use of cardiovascular medications can have a variety of
neuropsychiatric consequences. Many cardiovascular agents
cause higher rates of fatigue and sedation than placebo,
and case reports of medication-induced mood syndromes,
psychosis, and cognitive disturbances exist for many car-
diovascular drugs. Depression has been associated with -
blockers, methyldopa, and reserpine, but more recent syn-
theses of the data have suggested that these associations
are much weaker than originally believed. Though low
cholesterol levels have been associated with depression and
suicide, lipid-lowering agents have not been associated
with these adverse effects. Finally, cardiovascular medica-
tions may have beneficial neuropsychiatric consequences;
for example, the use of clonidine in patients with attention
deficit-hyperactivity disorder, the use of prazosin for
patients with post-traumatic stress disorder, and the use of
propranolol for performance anxiety and akathisia.
© 2007, LLS SAS Dialogues Clin Neurosci. 2007;9:29-45.Despite these cautions,many clinically important links
exist between use of cardiovascular medications and neu-
ropsychiatric syndromes.In this article,we will examine
each class of cardiovascular medication and review the
literature that describes the neuropsychiatric conse-
quences of medications within that class.At the end of
each section,we will synthesize the evidence into a “bot-
tom-line” statement that summarizes the clinical rele-
vance of the links between that particular class of car-
diovascular medications and neuropsychiatric symptoms.
Due to space limitations,we will not discuss drug inter-
actions between cardiovascular agents and psychiatric
medications in this review.
β-Blockers
A connection between the use of β-adrenergic blockers
(β-blockers) and neuropsychiatric symptoms,especially
fatigue and depression, has long been postulated.The
lipophilic β-blockers (eg,propranolol and metoprolol)
cross the blood-brain barrier much more easily than do
nonlipophilic β-blockers (eg,atenolol),and the lipophilic
β-blockers are thought to be associated with higher rates
of neuropsychiatric consequences.
The association between the use of β-blockers and the
development of depression has long been described;yet,
it remains controversial.Many case reports and several
small reviews have linked propranolol with depression,
7-11
and a trial by Thiessen et al
12 found that treatment with
propranolol was associated with higher rates of antide-
pressant prescriptions than with other β-blockers (both
lipophilic and hydrophilic).Similarly,Hallas
13 found that
new propranolol prescriptions were associated with high
rates of new prescriptions for antidepressants,compared
with prescription of diuretics.Further,a study that com-
pared quality of life among patients taking capropril,
enalapril,atenolol,and propranolol found that propra-
nolol was associated with significantly lower scores on a
global assessment of psychological functioning.
14 In con-
trast,a randomized,controlled trial in 312 patients who
received propranolol found no association between this
agent and depression at 1 year.
15 Furthermore,several of
the trials listed above did not take into account con-
founding variables (eg, benzodiazepine use and fre-
quency of outpatient visits) that were found to account
for the apparent relationship between use of β-blockers
and the diagnosis of depression;in one study there was
no association between use of β-blockers and depression
after making this correction.
16 Finally,a comprehensive
review of more than 5800 patients prescribed propra-
nolol found that this agent was rarely associated with
depressive symptoms, and that such symptoms usually
only arose after long-term use.
17
When trials have been expanded to include use of other
β-blockers,
18-20 the majority of studies and reviews have
found no association between β-blockers (as a class of
medication) and the presence of depression.Furthermore,
there has been mixed evidence that lipophilic β-blockers
are more strongly associated with depression than are
nonlipophilic agents.
20The most extensive analysis of the
association between β-blockers and depression,however,
was a meta-analysis of 15 trials (more than 35 000
patients).
21 Ko and colleagues found that β-blockers,as a
class, were not associated with a significant increase in
reports of depressive symptoms;furthermore,there were
no differences between outcomes following use of
lipophilic and nonlipophilic agents.
β-Blockers may be associated with adverse neuropsychi-
atric effects other than depression. Sedation, and to a
somewhat lesser degree, fatigue, have been associated
with use of β-blockers,both lipophilic and hydrophilic.
22,23
For example,approximately 25% of patients who take
atenolol report sedation—twice the number who report
sedation on placebo—but no substantial differences in
fatigue were observed between users of atenolol and
placebo.
24 In the large meta-analysis by Ko and col-
leagues
21 noted above, the authors found a statistically
significant,but small,increase in fatigue among patients
taking β-blockers: there were 18 additional reports of
fatigue per 1000 patients treated.Despite these reports
of sedation and fatigue, β-blockers do not appear to
cause cognitive dysfunction.
25,26 Psychosis,usually in the
context of delirium,has occurred rarely among patients
taking propranolol,
27-29 metoprolol,
30 and atenolol.
31
In addition to these adverse effects,there are also several
therapeutic neuropsychiatric uses of β-blockers. β-
Blockers,primarily propranolol,have been used to treat
anxiety. These agents are often considered to be the
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Selected abbreviations and acronyms
ACE angiotensin-converting enzyme
ADHD attention deficit-hyperactivity disorder
CCB calcium channel blocker
HMG CoA 3-hydroxy-3-methylglutaryl coenzyme A
PTSD post-traumatic stress disorder
SSRI selective serotonin reuptake inhibitoragents of choice for performance anxiety (eg, public
speaking).
32 In addition,β-blockers,especially the partial
agonist,pindolol (which also blocks serotonin [5-HT]1A
receptors) has been used adjunctively to enhance the
benefits of selective serotonin reuptake inhibitors
(SSRIs) in panic disorder
33,34 and obsessive-compulsive
disorder (OCD).
35 Finally,two recent studies found that
the administration of propranolol to patients immedi-
ately following trauma (within 6 hours) appears to
reduce the risk of developing post-traumatic stress dis-
order (PTSD).
36,37
β-Blockers have also been used to treat aggression
among patients with a variety of illnesses. Overall, the
evidence for any successful treatment of aggression with
any agent,or class of agents,is limited;however,β-block-
ers appear to be the best-supported class of medications
for the treatment of aggression related to traumatic brain
injury.
38 Furthermore,β-blockers appear to be effective
in reducing aggression among patients with a variety of
neuropsychiatric conditions (eg, schizophrenia and
dementia,with a behavioral disturbance).
39-41
Propranolol is a first-line choice for the treatment of
akathisia, an uncomfortable restless sensation that is
induced by use of antipsychotics and other agents that
affect dopamine neurotransmission (ie, are dopamine
blockers).
42 β-Blockers can also be used adjunctively to
reduce the effects of autonomic hyperactivity among
patients undergoing alcohol or benzodiazepine with-
drawal.
43,44 It is important to note that this treatment is
only adjunctive, and has not been shown to prevent
either delirium or seizures associated with alcohol with-
drawal.Finally,pindolol,because of its effects on 5-HT1A
autoreceptors, has been actively studied as a potential
augmenting agent for patients with depression.A recent
meta-analysis of nine randomized, controlled trials of
pindolol in combination with SSRIs found that pindolol
appears to speed up the response to SSRIs,although it
does not appear to improve overall response rates.
45
Bottom line: β-Blockers as a class are not clearly associ-
ated with depression; there is the most evidence for a
propranolol-depression link,but even this relationship is
equivocal. In contrast, β-blockers are associated with
increased rates of fatigue.Therapeutically, there is the
most evidence for the use of β-blockers (especially pro-
pranolol) in the treatment of akathisia and performance
anxiety. β-Blockers may help to prevent PTSD among
those suffering trauma and may reduce aggression,but
more data is needed.
Angiotensin-converting enzyme inhibitors
The neuropsychiatric consequences and therapeutic uses
of angiotensin-converting enzyme (ACE) inhibitors are
relatively limited.Captopril has been the ACE inhibitor
most closely associated with mood effects,potentially due
to its transport into the central nervous system (CNS) by
a protein carrier.
46,47 Several case reports and a small,
open trial have found captopril to be efficacious in the
treatment of major depression,
48-50 although larger,ran-
domized trials have not been performed.A randomized
trial that compared the effects of captopril,propranolol,
and methyldopa on quality of life,however,did find that
captopril was superior on global quality-of-life measures
than the other two antihypertensive medications.
51The
possible mood-elevating effects of captopril are further
supported by several reports of manic symptoms in asso-
ciation with use of captopril.
52-54There are fewer reports
of mood effects of other ACE inhibitors,though lisino-
pril has been associated with the induction of mania in a
single case report
55 and has been used in the adjunctive
treatment of depression in another report.
56 Psychosis
and delirium have been reported rarely with ACE
inhibitors.
57-59ACE inhibitors do not appear to have pro-
found cognitive effects,with small trials finding no cog-
nitive dysfunction
60 and perhaps even mild cognitive
enhancement
61 among patients taking captopril, but a
double-blind trial of an ACE inhibitor,ceranapril,
62 found
that this agent did not improve cognition among patients
with Alzheimer’s disease.ACE inhibitors also demon-
strate low rates of fatigue and sedation.
63,64
Angiotensin-II blockers
Angiotensin-II blockers (including losartan,valsartan,and
irbesartan) are relatively new agents, and as such, their
neuropsychiatric consequences are as yet relatively unde-
fined. For the most part, these agents do not appear to
have clear associations with depression,mania,psychosis,
delirium, cognitive impairment, or fatigue.
65-67 One case
report found that the combination of valsartan and
hydrochlorothiazide was associated with the onset of
depressive symptoms and a suicide attempt within 4 weeks
of initiation of this medication,and that the symptoms of
major depression then resolved within 10 days of its dis-
continuation,without other treatment.
68 In addition,losar-
tan was associated with the onset of psychosis and depres-
sion in an elderly patient; the symptoms resolved with
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31discontinuation,and then recurred with the reinstitution
of losartan.
69 Finally, with respect to the beneficial neu-
ropsychiatric effects of angiotensin-II blockers,a promis-
ing study found that patients prescribed losartan had sig-
nificant improvement in their cognitive function during
such treatment, in contrast to those treated with
hydrochlorothiazide.
70We are otherwise unaware of any
reports or studies of neuropsychiatric effects of these med-
ications; as clinical and research experience with these
agents grows,further neuropsychiatric consequences of
their use (beneficial or adverse) may become apparent.
Bottom line:ACE inhibitors and angiotensin II receptor
antagonists are associated with low rates of neuropsy-
chiatric side effects,though mood symptoms,psychosis,
and delirium have been reported.Therapeutically,there
is little data,though there is some suggestion that capto-
pril might improve depressive symptoms.
Calcium channel blockers
Calcium channel blockers (CCBs) are associated with
relatively low rates of adverse neuropsychiatric conse-
quences.Fatigue (and associated sedation) occurs at rates
greater than placebo,but it is an uncommon side effect
that rarely limits therapy.
71-73 Although CCBs theoreti-
cally have cognitive benefits,these agents have on occa-
sion been associated with delirium;verapamil and dilti-
azem have been named in single case reports, and
nicarpidine has been associated with confusion among
patients undergoing opiate withdrawal.
74-76
However, CCBs may have several beneficial neuropsy-
chiatric effects. For example, these agents have been
reported to have favorable effects in patients with mood
disorders.There have been multiple reports that described
the use of verapamil for the treatment of acute mania.
Several early case reports suggested that verapamil was
effective in the treatment of mania,
77,78 and small trials have
suggested that verapamil may be as effective as lithium in
the treatment of mania,
79-82 For example,in a trial compar-
ing verapamil and lithium in the treatment of 20 patients
with mania, Garza-Trevino and colleagues
79 found that
both treatments were effective,with no significant differ-
ences between lithium and verapamil.More recent trials
have found lithium to be more effective than verapamil (in
a single-blind trial)
83 and no more effective than placebo
(in a small,double-blind trial),
84 and interest in its use in
acute mania has generally waned.However,given the rel-
ative safety of verapamil in pregnancy and the encourag-
ing initial results with its use,a recent study of the use of
verapamil in the treatment of both pregnant and non-
pregnant women with bipolar disorder was conducted.
85
The authors found that verapamil was effective in the
treatment of acute mixed and manic states.In contrast to
the studies of verapamil, there has been little study of
other CCBs for acute mania;diltiazem was associated with
the development of mania in one case report.
86
Verapamil and other CCBs have also been used as main-
tenance treatment for patients with bipolar disorder.
87,88
A crossover trial of verapamil and lithium in the main-
tenance treatment of bipolar disorder found that these
agents were equally effective,
88 although there is some
suggestion that this agent is ineffective in patients with
refractory illness.
89 There have been three reports of
nimodipine’s efficacy in bipolar illness,
90-92 including a
small but well-designed on-off-on trial
90; however, the
largest trial showed relatively modest results in
monotherapy of patients with refractory bipolar affective
illness.Finally,a retrospective study found that diltiazem
was effective in the maintenance treatment of bipolar ill-
ness.
93 Despite this somewhat encouraging data in both
acute mania and maintenance treatment of bipolar ill-
ness,there have been no comprehensive trials of CCBs
(combining adequate numbers of patients with a
prospective,double-blind design) that would lead prac-
titioners to use these agents as front-line treatment for
patients with bipolar disorder at this juncture.
CCBs have been studied in the treatment of depressive
symptoms, with somewhat less encouraging results.
Verapamil was found to be less effective than amitripty-
line (a tricyclic antidepressant [TCA]) in a double-blind
trial for depression,
81 and ineffective for depression
among patients refractory to TCAs.
94 One trial found
that, in patients receiving electroconvulsive therapy
(ECT) there was greater mood improvement among
those taking nicardipine compared with placebo (the
study was originally designed to determine whether
nicarpidine improved ECT-associated cognitive impair-
ment;it did not).
95 Furthermore,because CCBs may be
effective in the treatment of cerebrovascular disease,
nimodipine has been used to augment antidepressant
treatment of patients suffering from vascular depres-
sion—ie,new-onset depression in older adults associated
with vascular lesions—in a pair of double-blind,placebo-
controlled studies.
96,97 Both studies found that nimodip-
ine was superior to placebo in reducing the symptoms
and lowering the rates of recurrence.
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32There have been limited trials regarding the use of CCBs
in the treatment of anxiety disorders.A double-blind trial
revealed modest anxiolytic effects of verapamil among
patients with panic disorder,
98 and open trials of diltiazem
and nimodipine for panic disorder also had positive
results;a trial of nifedipine for free-floating anxiety and
phobia had a negative result.
99
Bottom line: CCBs may be associated with fatigue in
some patients,but otherwise cause few neuropsychiatric
symptoms.Therapeutically,verapamil has been the most-
studied agent in several trials of mania and bipolar dis-
order,and has had mixed but generally positive results;
this agent may prove to be a viable option for patients
with bipolar disorder who are pregnant or fail first-line
therapies,though larger studies are needed.
Diuretics
Diuretics are generally associated with low rates of neu-
ropsychiatric adverse events.Thiazide diuretics, which
minimally cross the blood-brain barrier,
47,100 can more
indirectly result in neuropsychiatric complications due to
their effects on electrolytes (primarily sodium and cal-
cium)
101-105 and their effects on lithium excretion (effec-
tively doubling serum lithium levels when the two are
coadministered). One case series of eight patients has
reported a link between use of thiazide diuretics and
depression,although other evidence for this association
is lacking.
106 Hyponatremia and hypercalcemia associated
with the use of thiazide diuretics have been reported to
lead to delirium and psychosis.
102,103 Thiazides may also
exacerbate hyponatremia (and associated neuropsychi-
atric symptoms) caused by SSRIs via the syndrome of
inappropriate antiduretic hormone secretion
(SIADH).
104,105 Induction of lithium toxicity by thiazides
can result in multiple neurologic and psychiatric symp-
toms (including confusion, anterograde amnesia, and
severe tremor);one report has noted mania-like symp-
toms.
107 Overall,thiazide diuretics are not frequently asso-
ciated with fatigue,sedation,cognitive impairment,
108 or
other neuropsychiatric symptoms, and have not been
used therapeutically for neuropsychiatric conditions.
Other diuretics similarly have relatively few neuropsy-
chiatric effects.Loop diuretics (such as furosemide and
ethacrynic acid) are not associated with mood syn-
dromes,psychosis,or impaired cognition.However,long-
term use of furosemide is associated with thiamine defi-
ciency—one study found that over 90% of patients
taking 80 mg per day (and more than half of patients tak-
ing 40 mg per day) for CHF had a substantial deficiency
of thiamine.
109Thiamine deficiency can lead to Wernicke’s
encephalopathy (characterized by confusion,opthalmo-
plegia,and ataxia),and indeed,use of loop diuretics was
associated with this syndrome in one case report.
110
The carbonic anhydrase inhibitor acetazolamide can be
associated with fatigue and sedation,especially early in
treatment.
111 Epstein and Grant
112 found that nearly half
of carbonic anhydrase inhibitor-treated patients had a
mild syndrome of fatigue,malaise,anorexia,and depres-
sion,and that such symptoms were associated with aci-
dosis;there have been no further reports of depressive
syndromes with this agent. Delirium can occur rarely
with acetazolamide use;acetazolamide toxicity,which is
especially common in patients with renal failure,is char-
acterized by fatigue, lethargy, and confusion.
113-115
Acetazolamide may also have therapeutic neuropsychi-
atric consequences,especially among patients with apnea.
It stimulates central respiratory drive and may therefore
provide benefits in both central and obstructive sleep
apnea.
116,117 In addition,there has been a single case report
of its use in acute mania
118 and a small study found that
acetazolamide,particularly when combined with an anti-
convulsant,might prove beneficial to patients with refrac-
tory symptoms in bipolar disorder.
119 Finally,Inoue and
colleagues
120 used acetazolamide to treat patients with a
variety of atypical psychoses, and found that approxi-
mately 70% of patients improved.
Bottom line: Diuretics most often cause neuropsychiatric
symptoms indirectly,through electrolyte abnormalities
(thiazides) or vitamin deficiencies (loop diuretics).
Acetazolamide is associated with fatigue and with delir-
ium in renal failure.Small studies suggest that acetazo-
lamide may provide benefits in sleep apnea or bipolar
disorder.
Centrally acting agents
Clonidine
Clonidine,a central α-adrenergic agonist,is associated
with a number of neuropsychiatric effects.Fatigue and
sedation are the most common effects, with sedation
occurring in one third or more of patients.
121-123 Mood dis-
turbance has been infrequently described with clonidine;
pooled information suggests that depression occurs in
approximately 1% to 2% of patients taking clonidine,
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33and there are no case reports of clonidine-induced
depression or mania,though there has been one report
of hypomania in a patient with pre-existing depres-
sion.
121,122 Hallucinations can occur with clonidine,though
rarely;one case report describes a man with two episodes
of hallucinations associated with clonidine that resolved
with discontinuation in both instances.
124 Finally,clonidine
may also affect cognition in certain patients.It has been
associated with cognitive slowing,
123,125 and there have
been at least seven case reports of delirium associated
with the use of clonidine.
126
However,the neuropsychiatric consequences of clonidine
are most often those associated with its therapeutic uses.
Clonidine has been used to treat a variety of neuropsy-
chiatric illnesses.Clonidine is frequently used (as second-
line monotherapy or as an adjunctive agent) to treat
attention deficit-hyperactivity disorder (ADHD),par-
ticularly among patients with comorbid tics or prominent
hyperactivity,impulsivity,or aggression.
127-129 Clonidine is
generally less effective than are psychostimulants in the
treatment of ADHD,but a recent meta-analysis found
that clonidine is moderately efficacious as monotherapy
for symptoms of ADHD.
127 Another large study found
that clonidine was efficacious both as monotherapy and
as an adjunctive agent for patients with ADHD and
comorbid tics.
128
In addition,clonidine is frequently used to reduce symp-
toms of opiate withdrawal;clonidine decreases norepi-
nephrine release during opiate withdrawal by binding
presynaptically to the α2 receptors.
47A comprehensive
review
130 of clonidine use for opiate withdrawal found
that withdrawal symptoms were generally reduced simi-
larly by clonidine and by a tapering schedule of long-act-
ing opiates (eg,methadone).Rates of completion of with-
drawal protocols were similar with use of clonidine and
an opiate taper.However,subjects had more side effects
with clonidine and stayed in treatment longer when opi-
ates were used.Similarly,clonidine appears to be mar-
ginally less effective than buprenorphine (a mixed opi-
ate agonist/antagonist) for opiate withdrawal.
131
Other therapeutic uses for clonidine have included its use
in the treatment of alcohol withdrawal, for which it
appears to reduce many of the adrenergic symptoms
associated with such withdrawal
132,133;however,as with β-
blockers,clonidine is best used—if at all—as an adjunc-
tive agent,as there is no evidence that this agent in effec-
tive in reducing rates of seizure, psychosis, or delirium
associated with alcohol withdrawal.
134-136 Clonidine has
been used in the treatment of Tourette’s syndrome (TS).
It is moderately effective in reducing tics and other symp-
toms of this disorder.
137-140 Finally,use of clonidine has also
been reported in a variety of other conditions,including
Korsakoff’s syndrome (a neuropsychiatric syndrome
caused by thiamine deficiency),
141,142 bipolar mania,
143 and
conduct disorder,
144 though there is insufficient evidence
to adequately assess the benefits of clonidine in these
conditions.
Bottom line: Clonidine is consistently associated with
fatigue and sedation;delirium is infrequently associated
with its use.Clonidine also has several therapeutic uses
for neuropsychiatric disorders,serving as a first- or sec-
ond-line treatment for ADHD and Tourette’s syndrome;
it is also commonly used to reduce symptoms of opiate
withdrawal.
Methyldopa 
Methyldopa is infrequently used in clinical practice,except
in patients with pregnancy-induced hypertension.It may
reduce blood pressure via central α2agonism,and may also
act as a false (norepinephrine) neurotransmitter.
47,123 As
with many cardiovascular agents,the most common neu-
ropsychiatric consequences of methyldopa use are seda-
tion and fatigue;a comprehensive review by Paykel and
colleagues
123 found that sedation occurs in approximately
one third of methyldopa-treated patients,with high rates
of associated fatigue.For example,Levine and colleagues
found that patients treated with methyldopa had lower
self-reported quality of life and vitality than did those tak-
ing captopril in a 24-week trial,
145 and a similar trial found
that patients on methyldopa showed more fatigue than did
those on captopril.
146 Impaired concentration and
decreased performance on measures of neuropsychologi-
cal functioning have been reported with methyldopa,
147,148
though a more recent trial found no cognitive impairment
with methyldopa compared with five other antihyperten-
sives;
149 such cognitive effects may be due to sedation.
However,perhaps the best-known neuropsychological
consequence of methyldopa use is depression.It appears
that depressive symptoms may occur more frequently
with methyldopa than with most other antihypertensive
agents,and it is thought that this effect may be related to
reduced norepinephrine levels.An early study of methyl-
dopa found increased rates of depression with this agent,
especially in those with a history of depression,
150 and a
study of elderly patients found methyldopa to be more
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strongly associated with depressive symptoms than were
β-blockers;
148 overall,it appears that reported depressive
reactions to methyldopa often occur in patients with
prior depressive episodes.
151,152 In contrast, a critical
review of the literature by Long and Kathol
153 found no
clear evidence that methyldopa was associated with the
development of depressive symptoms, in contrast to
reserpine.Similarly,a review of 80 patients found no sig-
nificant association between methyldopa and depres-
sion.
154 Overall,the association between methyldopa and
depression is similar to that with β-blockers:suggestion
of a connection in early case reports and small trials,with
larger reviews unsupportive of a definitive association.
Methyldopa, among its other actions, is a dopa decar-
boxylase inhibitor,and was reported to work synergisti-
cally with levodopa in patients with Parkinson’s disease
in several early reports in the 1970s.
155-157 However,there
have been no recent reports to our knowledge,and it is
not used in clinical practice for this indication, having
been replaced by the dopa decarboxlyase inhibitor,car-
bidopa.Finally,methyldopa has been associated with the
onset of psychotic symptoms and acute confusional
states,although these effects are rare.
158,159
Bottom line: Methyldopa is clearly associated with
fatigue and sedation.In contrast to early studies linking
methyldopa with depression, later reviews and studies
have found this association to be relatively weak.Other
neuropsychiatric symptoms are uncommon.
Reserpine
Reserpine,an older antihypertensive medication that is now
rarely used,can have a variety of neuropsychiatric effects.
This agent acts by inhibiting the uptake of monoamine neu-
rotransmitters into storage granules,resulting in the metab-
olism of these neurotransmitters by monoamine oxidase.
This depletion of catecholamine neurotransmitters results
in its antihypertensive effects and likely contributes to its
association with depression and fatigue.
47
Reserpine has long been associated with the onset of
depressive symptoms,with a bevy of reports in the 1950s
that linked reserpine use with depression,
160-163 and a later
review by members of our group citing an incidence of
up to 15%.
164 However, other (generally more recent)
reports call this association into question. First, the
depressive symptoms associated with use of reserpine
appear to include sedation,malaise,and fatigue,but may
not meet formal criteria for major depression
47,162; those
who meet the full criteria tend to receive higher doses
and to have a history of depression. Furthermore, two
relatively large studies, one examining the onset of
depressive symptoms among patients taking diuretics,β-
blockers, and reserpine in over 4000 patients,
165 and a
large study of hypertension in the elderly that used low
doses of reserpine,
166 found very low rates of depression
with reserpine use. In summary, reserpine is unques-
tionably associated with fatigue and sedation in a sub-
stantial subset of patients,
167,168 and may be associated
with the development of depressive symptoms, though
this latter association is not as strong or as clear as once
thought.
169
Reserpine may also affect cognition in the elderly,
170 most
likely due to its sedative properties,though one study of
five antihypertensive agents found no effect of reserpine
on cognition in the elderly.
171 Psychosis has been associated
with reserpine withdrawal—presumably due to rebound
increases in dopamine levels after discontinuation.
172,173
Finally,reserpine has been used for treatment purposes.
It has been used in cases of refractory mania with good
effect,
174-176 and it was,along with chlorpromazine,one of
the first agents used to treat psychosis.Its antipsychotic
effects and tolerability appear inferior to those of current
antipsychotic medications,
47 but this agent is still used,
though rarely,in combination with atypical antipsychotics
in refractory cases or to treat psychosis associated with
phencyclidine.
176-180At one time,reserpine,especially via
intravenous administration,was thought to have poten-
tial as a rapid-acting antidepressant,but its effects appear
to be transitory and overall less effective than standard
treatments.
181
Bottom line: Reserpine is associated with both sedation
and daytime fatigue. Incidence of depression may be
elevated among patients taking reserpine. However,
other (generally more recent) reports question this
association. It may provide benefit to patients with
mania or psychosis, but is not first-line therapy for
either condition.
α-Adrenergic agents
The α1-adrenergic antagonists prazosin,doxazosin,and
alfuzosin are used as antihypertensive agents and to
treat symptoms of benign prostatic hypertrophy.In gen-
eral, there are few adverse neuropsychiatric conse-
quences associated with these medications. Fatigue is
the most common neuropsychiatric effect,occurring inassociation with all α1 antagonists.
182-184This effect is rel-
atively infrequent (presenting in approximately 5% to
15% of patients),
182,183 but it does occur more often than
with placebo, and can lead to its discontinuation.
Depression is not consistently associated with this class
of agents, although there have been rare occurrences
reported in association with prazosin use.
185 Sleep dis-
turbance and anxiety can occur with these agents,
though such symptoms are usually mild
186,187; there has
been a single case report of psychosis associated with
doxazosin.
188 Finally, aside from a small case series
describing encephalopathy in three patients with end-
stage renal disease,
189 α1 antagonists have not been fre-
quently implicated in the development of delirium,and
a study of nonelderly patients found that prazosin-
treated patients performed slightly better on cognitive
testing than did patients given hydrochlorothiazide
(HCTZ) or propranolol.
190
With respect to therapeutic uses, prazosin has been
increasingly studied in the treatment of PTSD; it is
thought to reduce the abnormal hyperadrenergic activ-
ity seen in patients with this illness.Multiple studies have
found that prazosin reduces nightmares and sleep dis-
turbances among patients with PTSD,
191-195 and there has
been more recent evidence that prazosin may have
broader therapeutic effects in this disorder,reducing day-
time symptoms and the overall burden of PTSD symp-
toms.
191,196
Bottom line: Fatigue is the most common neuropsychi-
atric side effect associated with α-adrenergic antagonists;
other neuropsychiatric side effects are infrequent.
Prazosin appears to improve sleep-related symptoms of
PTSD and may reduce the overall burden of symptoms
in this disorder.
Vasodilators
Hydralazine
Hydralazine,a systemic vasodilator,the use of which is
usually reserved for patients with severe hypertension,
occasionally has neuropsychiatric side effects.Fatigue or
asthenia occur slightly more often with hydralazine than
with placebo, although this effect is not prominent.
Hydralazine has been associated on rare occasions with
the direct onset of depression,
197 mild anxiety,
198 psy-
chosis,
199 and delirium (due to withdrawal of hydralazine
that has led to acute hypertension in a patient receiving
hydralazine for afterload reduction).
200 Furthermore,
hydralazine does not appear to adversely affect cognition
(with longer-term use) in the elderly.
201
One neuropsychiatric consequence of hydralazine use is
systemic lupus erythematosus;in fact,hydralazine is per-
haps the most common cause of drug-induced lupus.
202
However,drug-induced lupus affects the CNS less com-
monly than does idiopathic lupus, and though mood
symptoms and fatigue may occur with hydralazine-
induced lupus,more serious neuropsychiatric reactions
have not been clearly described.
203
Nitrates (nitroglycerin, isosorbide dinitrate, and 
nitroprusside)
Nitrates,most commonly used to treat angina,have min-
imal neuropsychiatric side effects.The rapid reduction in
blood pressure caused by these agents can theoretically
lead to an acute confusional state, and, indeed, nitro-
prusside-induced delirium has occurred in at least one
patient.
204A single case report has also described hallu-
cinations and suicidal ideation in a patient taking isosor-
bide dinitrate,
205 but mood symptoms or psychotic symp-
toms have not otherwise been associated with nitrate
medications.
Bottom line:Vasodilators are generally associated with
low rates of neuropsychiatric consequences.Hydralazine
is a leading cause of drug-induced lupus, but this syn-
drome affects the central nervous system much less com-
monly than the idiopathic form of the disorder.
Antiplatelet and anticoagulant agents
Aspirin (salicylic acid) has few neuropsychiatric conse-
quences. It has not been consistently associated with
mood symptoms,fatigue,sedation,anxiety,psychosis,or
delirium when used at therapeutic doses.However,sali-
cylate intoxication can lead to psychosis and delirium,
possibly as a result of acidosis.
206-208Therapeutically,aspirin
may have beneficial effects in patients with dementia.
There has been some suggestion that aspirin may reduce
the rate of cognitive decline in the elderly, particularly
among patients with vascular dementia 
209,210 by reducing
the risk of recurrent vascular events, although a recent
systematic review of aspirin for vascular dementia found
no such evidence.
211 Nilsson and colleagues
212 also found
that high-dose aspirin (325 mg/day) use was associated
with reduced rates of development of Alzheimer’s dis-
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ease—presumably as a result of its anti-inflammatory
effects—but more comprehensive study is needed.Finally,
the anti-inflammatory effects of aspirin have been postu-
lated to have potential benefit in depression,given recent
suggestions that inflammation may contribute to the
pathophysiology of this disease.There has been a single,
small, open trial in 24 depressed patients who had not
responded to a 4-week trial of SSRIs;the authors found
that the addition of aspirin to the SSRI led to rapid and
sustained response in approximately one half of
patients.
213 However,much more research is required to
determine whether the addition of aspirin to an antide-
pressant regimen for depression is indicated.
The antiplatelet agent,clopidogrel,has not been associ-
ated with significant neuropsychiatric consequences;as
experience with this agent increases,adverse neuropsy-
chiatric effects or therapeutic uses for neuropsychiatric
disorders may become apparent.Similarly,the anti-coag-
ulant medications, heparin and warfarin, are not com-
monly associated with neuropsychiatric effects.
Bottom line: Use of antiplatelet and anticoagulant med-
ications has not been consistently associated with sub-
stantial neuropsychiatric consequences. Aspirin may
cause delirium in toxicity.
Selected antiarrhythmic medications
Class I agents 
These agents, which exert their therapeutic effects by
blocking sodium channels,were commonly prescribed for
many years,especially among acutely ill patients in inten-
sive care settings.Their popularity has waned recently,
though they remain in use.
Disopyramide (Class Ia)
The majority of neuropsychiatric consequences of
disopyramide use result from the anticholinergic prop-
erties of this medication.Delirium can result from such
anticholinergic effects,
214 and there have been case
reports of disopyramide-associated psychosis.
215,216 Other
neuropsychiatric consequences of use are uncommon.
Therapeutically, disopyramide has been studied in the
treatment of neurally mediated hypotension among
patients who suffer from chronic fatigue;small studies
suggest that it may provide benefit to persons whose
fatigue is related to such hypotension.
217,218
Procainamide (Class Ia)
Although procainamide is generally associated with low
rates of neuropsychiatric side effects, procainamide-
induced psychosis has been reported in a variety of case
reports involving seven patients.
219-223 The mechanism of
this association is ill-defined,and it is not clear whether
some of these psychotic symptoms occurred in the broader
context of delirium, as disorientation has also been
reported as an uncommon side effect of this medication.
224
Mania has also been reported in association with this
agent.
225 Finally,like hydralazine,procainamide is a lead-
ing cause of drug-induced lupus;this usually occurs after
long-term exposure,and neuropsychiatric manifestations
are uncommon.
226Among its more common side effects,
fatigue can occur,but it is generally mild.
Quinidine (Class Ia)
Quinidine,a derivative of the cinchona plant,has been
associated with neuropsychiatric events,most famously
the constellation of symptoms known as cinchonism.
Cinchonism may result in delirium along with a variety
of effects on hearing and vision,with gastrointestinal side
effects,and with cardiovascular events
227,228;psychosis has
also occurred in the context of quinidine use.
229,230 More
chronic cognitive syndromes have also been reported
rarely with use of quinidine.
231-233 Quinidine does not
appear to be associated with mood changes,and fatigue
and sedation may occur but are not prominent.
Lidocaine (Class Ib)
Systemic use of lidocaine has been associated with a vari-
ety of neuropsychiatric effects.Lloyd and colleagues,
234 in
a review of the neuropsychiatric effects of antiarrhyth-
mics,report that delirium,psychotic symptoms,and anx-
iety may be consequences of lidocaine use.Furthermore,
a specific review of 15 cases of adverse neuropsychiatric
effects of lidocaine found that mood symptoms and
apprehension/anxiety were the most common such
effects; confusion and psychotic symptoms (hallucina-
tions and delusions) were also common in this cohort.
235
Flecainide (Class Ic)
Flecainide is now rarely used;as with other class I agents,
the literature on the neuropsychiatric consequences of itsuse has been limited to case reports.Flecainide has been
associated with psychosis,especially in toxicity,with new-
onset paranoia,
236 hallucinations, and dysarthria.
237
Delusions, hallucinations, and depressed mood
238 have
also described in a report of three cases.
Bottom line: Most class I antiarrthymic agents have been
associated with psychosis and delirium in case reports.
The syndrome of cinchonism associated with quinidine
may include sensory changes along with delirium, and
procainamide is a cause of drug-induced lupus.
Class III agents
Amiodarone
In contrast to the above antiarrythmics,amiodarone has
been increasingly used in recent years, especially for
patients with atrial fibrillation (AF).Amiodarone is listed
as a class III antiarrthymic agent that is thought to act via
sodium, potassium, and calcium channel blockade.The
structure of amiodarone is similar to that of thyroid hor-
mone,and thyroid abnormalities occur in approximately
15% of patients taking amiodarone due to its high iodine
content and its direct toxic effects on the thyroid
239;both
hypothyroidism (more common) and hyperthyroidism
may occur.Through this indirect mechanism,neuropsy-
chiatric effects of amiodarone may occur, as hypothy-
roidism is commonly associated with fatigue and depres-
sive symptoms (and occasionally psychosis),
240 while
hyperthyroidism can be associated with sleep disturbance,
anxiety,apprehension,and,at times,depressive or mani-
form symptoms,with or without psychosis.
241 In addition,
amiodarone has been directly associated with delirium,
242-245
depressive symptoms,
246,247 and fatigue
251;these effects have
not been studied comprehensively but do not appear to be
frequent complications of amiodarone use.
Bottom line: Amiodarone is associated with thyroid
abnormalities in 15% of patients,and untreated thyroid
dysregulation can lead to a variety of mood,cognitive,
and psychotic symptoms. In contrast, direct neuropsy-
chiatric effects of amiodarone are uncommon.
Digoxin
Derived from the foxglove plant,Digitalis lanata,digoxin
is used in the treatment of congestive heart failure and
as a rate control agent for atrial fibrillation and atrial flut-
ter.Digoxin has been associated with a wide variety of
neuropsychiatric side effects,both in toxicity and at ther-
apeutic levels. Keller and Fishman,
47 in their excellent
review of the neuropsychiatric effects of cardiovascular
medications, described the range of neuropsychiatric
symptoms associated with digoxin.Such effects include
fatigue,depression,psychosis,and delirium,and the pre-
scribing information for digoxin reports “mental distur-
bance” in 5% of patients taking digoxin (vs 1% with
placebo).
249 It appears that cognitive effects,such as delir-
ium,may be the most common neuropsychiatric conse-
quences of digoxin use,as over 80% of digoxin-associ-
ated adverse psychiatric effects reported to a Canadian
national registry were classified as “encephalopathy.”
250
Digoxin-associated delusions and other psychotic symp-
toms often occur in the context of delirium, although
rarely digoxin toxicity may present with isolated psy-
chotic symptoms.
251-254 In addition,visual changes (such as
blurred or yellow vision) and hallucinations are relatively
common side effects of digoxin use. Depressive symp-
toms have been associated with digoxin in small trials
and case reports, and digoxin toxicity can sometimes
masquerade as depression.
255-257 Depression linked with
use of digoxin—as with many mood syndromes associ-
ated with cardiovascular medications—presents with
prominent fatigue, low appetite, and impaired sleep.
47
Despite these reports,however,larger prospective trials
have not supported a strong link between digoxin and
the development of depression.
258,259
Bottom line: Digoxin is associated with delirium and
other cognitive effects, especially in toxicity. Visual
changes and hallucinations may also occur with digoxin
use,even at normal serum levels.
Lipid-lowering agents
Gemfibrozil, niacin, and bile acid sequestrants
The lipid-lowering agent gemfibrozil is not associated
with significant neuropsychiatric consequences;there are
no clear associations with mood or psychotic symptoms,
delirium or dementia are uncommon, and fatigue
appears to occur at rates similar to placebo.Niacin was
once thought to have beneficial neuropsychiatric
effects—with small,but suggestive,reports in the 1950s
and 1960s that nicotinic acid was effective in the treat-
ment of depression and schizophrenia.
260-263 However (as
with many apparent associations we have discussed),
once systematic reviews were performed,there appeared
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to be no evidence for an association between nicotinic
acid and antidepressant or antipsychotic effects.
264,265
Adverse neuropsychiatric effects of niacin are uncom-
mon.Bile acid sequestrants (such as cholestyramine) also
have low rates of associated neuropsychiatric effects;
there has been a report of cholestyramine-induced meta-
bolic acidosis leading to delirium.
266 However,the most
frequently-used lipid-lowering agents are the 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors (“statins”),and because of their widespread
use these agents require further discussion.
HMG-CoA reductase inhibitors 
The HMG-CoA reductase inhibitors are in widespread
use.Overall,these agents have been associated with few
neuropsychiatric effects.
267-269 Lovastatin and pravastatin
are more lipophilic than the other agents (such as ator-
vastatin and pravastatin),and therefore they can more
easily cross the blood-brain barrier and potentially cause
more neuropsychiatric effects;however,clinical experi-
ence has not found great differences between these
agents in this regard.
One important area of interest concerns cholesterol levels
and the risk of mood symptoms and aggressive acts.Low
cholesterol levels have been correlated with depression,
aggression, and suicide in several longitudinal studies.
Several early studies found a correlation between low cho-
lesterol and deaths from suicide,
270-272 and a large longitu-
dinal study found that patients in the lowest one third of
cholesterol levels had elevated rates of suicide.
273A review
of additional studies similarly found a low cholesterol-sui-
cide link,
272 even with correction for confounding factors;
such low levels of cholesterol appears associated with
depressive symptoms as well as frank suicidality.
274 The
mechanism of this association is unclear,but is thought by
some to be mediated by serotonergic neurotransmission.
275
Despite these findings,lowering serum cholesterol with
statins has not been associated with increased rates of
depression,noncardiac deaths,or suicide in several large
prospective studies and a meta-analysis.
276-279 Overall,
there have been only a handful of reports of depressive
symptoms associated with statin use,
280-282 and prospective
studies of statins’ effects on mood and cognition have
found that these agents do not consistently cause
depressed mood or impair cognition.
276,277,283,284
The second area of interest with respect to these med-
ications is their potential ability to prevent or treat
Alzheimer’s dementia. Some authors have postulated
that statins’ apparent ability to decrease Aβ peptides
(thought to be part of an inflammatory pathway in
Alzheimer’s disease) may lead to the therapeutic use of
statins for patients with Alzheimer’s dementia.
285At this
stage, several studies both supporting and refuting the
utility of statins in the prevention and treatment
Alzheimer’s disease have been published.For example,
a small study of atorvastatin found that this agent pro-
vides clinical benefit in patients with mild-to-moderate
Alzheimer’s,
286 and a large case-control study found that
patients taking statins had a reduced incidence of
Alzheimer’s dementia.
287 In contrast,other well-designed
studies have found no such benefit,
288,289 and further
research is needed.
Otherwise,the statins appear to have few neuropsychi-
atric consequences, with occasional reports of anxiety,
sleep disturbance (especially with lovastatin),and fatigue,
but no other substantial neuropsychiatric effects.
267-269,290
Bottom line: Lipid-lowering agents are associated with
low rates of neuropsychiatric effects.Low absolute cho-
lesterol levels have been correlated with depression and
suicide,but several large trials of HMG-CoA reductase
inhibitors have not found increased rates of depression
and suicide associated with these drugs.Statins may have
therapeutic effects in the prevention or treatment of
Alzheimer’s dementia;studies thus far have had mixed
results and further research is needed.
Conclusion
In summary,the vast majority of neuropsychiatric con-
sequences of cardiovascular medications are documented
by case reports or open trials that are unable to defini-
tively answer questions about causality.Indeed,a num-
ber of assumed associations (eg,between β-blockers and
depression) appear weak or nonexistent when more
comprehensive prospective trials are performed.Despite
this,numerous cardiovascular medications can have neu-
ropsychiatric side effects,ranging from mood symptoms
to cognitive effects to psychosis,and though a given agent
may not consistently cause neuropsychiatric symptoms
in the general population,idiosyncratic reactions are pos-
sible.Cardiovascular medications can also have benefi-
cial neuropsychiatric effects (eg,the use of clonidine in
ADHD and tic disorders and prazosin for sleep distur-
bance in PTSD).With more formal study of the associ-
ations between cardiac medications and their neuropsy-chiatric effects, clinicians will be better able to make
fully-informed prescribing decisions for their patients. ❏
The authors would like to thank Sara Nadelman for editorial assistance.
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Consecuencias neuropsiquiátricas de los
medicamentos cardiovasculares
El empleo de medicamentos cardiovasculares puede
tener una variedad de consecuencias neuropsi-
quiátricas. Muchos fármacos cardiovasculares pro-
vocan con mayor frecuencia fatiga y sedación res-
pecto del placebo y también existen muchos
reportes de casos de síntomas afectivos, psicosis y
trastornos cognitivos inducidos por varios de estos
medicamentos. Se ha asociado la depresión con
beta-bloqueadores, metildopa y reserpina, pero
análisis recientes de estos datos han sugerido que
estas asociaciones son mucho más débiles que lo
que originalmente se pensaba. Aunque los niveles
reducidos de colesterol se han asociado con depre-
sión y suicidio, los fármacos reductores de lípidos no
se han asociado con estos efectos adversos. Por
último, los fármacos cardiovasculares pueden tener
efectos neuropsiquiátricos útiles; por ejemplo, el
empleo de clonidina en pacientes con trastorno por
déficit atencional con hiperactividad, el uso de pra-
zosin en pacientes con trastorno por estrés pos-
traumático y la indicación de propranolol en la
ansiedad de rendimiento y en la acatisia.
Conséquences neuropsychiatriques des trai-
tements cardiovasculaires
Les traitements cardiovasculaires peuvent avoir des
conséquences neuropsychiatriques variées. De nom-
breux produits cardiovasculaires induisent une
fatigue et une sédation plus importantes que le pla-
cebo. Des troubles cognitifs, de l’humeur et psycho-
tiques ont été considérés comme provoqués par un
grand nombre de ces traitements cardiotropes. La
dépression a parfois été associée aux -bloquants,
à la méthyldopa et à la réserpine, mais des données
plus récentes laissent penser que ces associations sont
beaucoup moins importantes qu’initialement pres-
senties. Bien que des cholestérolémies basses aient
été associées à la dépression et au suicide, les hypo-
lipémiants n’ont pas été incriminés dans de tels effets
indésirables. Les traitements cardiovasculaires peu-
vent finalement avoir des conséquences neuropsy-
chiatriques bénéfiques : par exemple, l’utilisation de
la clonidine chez les patients atteints d’un déficit de
l’attention/hyperactivité, l’utilisation de la prazosine
pour ceux souffrant d’un syndrome de stress post-
traumatique, et l’utilisation du propranolol pour
l’anxiété de performance (trac) et l’akathisie.
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